Staff out, instruments down—coping as the year begins

We’re having crisis planning for staffing and it’s involving multiple levels of the organization; it’s affecting lab. Whatever plans we have, each day we get new resignations, and today we’re getting more people out with COVID. With the crisis staffing, it impacts the level of care we have in some places. We’re having to cut back or centralize some testing that normally we wouldn’t.

There are multiple supply issues. We have incident command structures set up for the tubes, staffing, and blood shortage.

Tell us more about crisis planning.
Dr. Anthony (Allina): We have a system group and a format that we go through with different triggers that could be pulled at different times—for example, triggers where we might be able to manage things by shifting people around. But then we get to the point where we can’t manage things by shifting people around, and that’s when we start to shift the work around and that affects the services we put on site.

We’re standardized across the system—same equipment, procedures, electronic medical records—so a person can volunteer to work at a different site. But the issue then is, what about when they volunteer to go to a different site but they’re not, for example, a blood bank person? We say while that person is covering that hospital—and smaller hospitals might only have one person on duty—they would only be able to issue emergency group O red cells. That requires communication with the team at the site and careful coordination so everybody knows what they would do with a bleeding patient and what their expectations for blood availability are during those hours when that volunteer is the only person there. Managing multiple things like this with fewer resources and with disruptions is creating the majority of our work now.

People throw out solutions to problems, but you have to connect the dots. If we did this, would it really increase the staff we have available? It requires a lot of talking and coordination to try to figure out what strategies are worth looking at or trying. At this point, it’s taking all of our resources.

Bob Carlson, tell us what’s going on at NorDx and MaineHealth.
Robert Carlson, MD, medical director, NorDx, MaineHealth: We had our highest number of positives yesterday—more than 1,000, with an overall positivity rate of around 21.8 percent. The asymptomatic population, which includes some of the prescreening, is running around 18 to 19 percent. We’ve run a couple of variant panels over the past few months. It used to be 100 percent delta. About a week and a half ago, we could see the non-delta starting to creep in, which we’re assuming is omicron. We’re running a plate today and I expect omicron to be the vast majority of cases.

Staffing remains critical for the phlebotomy PSCs as well as the lab personnel. We run our COVID testing on the QuantStudio using 96-well plates. It’s extremely manual. We will hit our 1 million COVID tests mark in the next two weeks, and for a manual process to have that many tests is phenomenal. I am proud of our staff but they are weary.

Barb Bigler, what’s going on at ACL Labs in Chicago?
Barbara Bigler, president, ACL Laboratories, Rosemont, Ill., and West Allis, Wis.: We’re testing almost 50,000 samples weekly with the ability to do more. We have experienced some problems with the rapid PCR testing availability, which would improve if we had unlimited access to all the testing possible. Our central labs are running 24/7. We are running about a 35 percent positivity rate.

In Illinois the prevalent virus is delta whereas in Wisconsin it’s omicron. Illness and hospitalization are spiking in Illinois a little more than in Wisconsin, but Wisconsin is busy with hospital beds with the limitations of having only so many beds and staff. In addition to labor shortages, we are experiencing staffing issues due to illness.

Let’s hear from your colleague Mick Runnoe.
Mick Runnoe, VP of Laboratory Operations, ACL Laboratories, West Allis, Wis.: We have 63 laboratory employees out with COVID. It becomes difficult to manage all the different sites and locations, which is why I paid keen attention to Diana’s report about changing hours of draw on the hospital. I’m going to take that back.

We’re not sequencing at this time, so we’re not able to identify variants. Our medical staff is having the same issues with the monoclonal antibody, and they’ve decided to pull that off the shelf with the 75 percent omicron in Wisconsin. Illinois numbers are catching up.

John Waugh, can you weigh in from Detroit?
John Waugh, MS, MT(ASCP), system VP, pathology and laboratory medicine, Henry Ford Health System, Detroit: The most disruptive are absences, and absences on very short notice. Children get COVID and mom and dad get it two days later, and now they’re all out of work. At Henry Ford we have more than 200 employees out this morning. But that doesn’t tell the full story because there were another 300 in the phone queue awaiting decisions, and our employee health clinics are overrun trying to evaluate these individual cases and balance the 10-day, seven-day, five-day changing guidance.

We have not reinstituted presurgical or preprocedural testing. We’re still doing surgeries. Our positivity rate for the last week has been 40 to 45 percent of all patients tested. We have a low availability of monoclonal antibodies. I heard this morning there are 30 doses and they will all be used immediately and be gone today.

The other challenge is, we have a number of temporary nursing agency contracts ending with the turn of the year, and a number of them are not being renewed. Or the ones being renewed are featuring new staff who have to be onboarded and oriented to all of our systems here.

We did validate patient self-collect of nasal samples, which we think will be helpful as we get that fully instituted in our employee health clinics and some of our screening areas. That was done by taking a provider collect for 250 samples and then a patient collect for 250 samples and comparing the results of the two. We had a more than 98 percent correlation, and that was for a group with ages ranging from 19 to 94. There was a high level of confidence that patients and employees will be able to self-collect samples, saving the process of nasopharyngeal.

I’m sure you share Jim Crawford’s empathy for the CDC and the dilemma it faces. But as a consumer, as a family man, do you agree with me there’s a bit of confusion on the line for a consumer?
John Waugh (Henry Ford): There’s a lot of confusion out there. The dilemma is the environment we’re operating in is not on play; it’s on fast-forward and things are changing too rapidly. Some of the information people receive are forecasts on news media, and it takes time to evaluate that at a local and state level versus the federal level, and then even within our own organizations to determine whether we’re going to make a change in our policies and then communicate that internally to stakeholders.

Stella Antonara at OhioHealth, tell us what’s going on in Columbus.
Stella Antonara, PhD, D(ABMM), medical director of microbiology, OhioHealth: Our overall positivity rate throughout our system is more than 45 percent, consistently for the past week, and our urgent care sites reached a positivity rate of 55 percent. At this time, we’re wondering whether it’s worth testing anymore. We’re at the highest level of performing daily testing, more than 2,500 per day throughout our system. We never stopped doing preadmission testing. Even through the delta surge, our preadmission testing for our asymptomatic people was relatively low; it may have reached six percent at the height of the delta surge, but at this point we’re seeing close to 20 percent.

We do not have sequencing capability in-house. One of the assays we use is the TaqPath assay. We monitor the S gene dropout for the samples we run, and the dropout rate is above 60 percent, sometimes 80 percent. CDC projects for our area to be at about 70 percent for omicron, consistent with the rates we see.

Eric Carbonneau at TriCore, I’m hoping the sun and New Mexico weather will give us a nicer story.
Eric Carbonneau, MS, MT(ASCP), director, laboratory operations, Woodward Labs and TriCore Research Institute at TriCore Reference Laboratories: We’re at 23 percent positive and omicron is rising. We’re still in crisis care for our hospitals.

We have a lot of the film industry here in New Mexico and we’ve done their surveillance. We’re starting to see the film crews coming in as positive and potentially impacting their ability to work. So we’re seeing a lot of that impact in our community, as well as requests for employer-based testing and surveillance.

We’re seeing, in addition to the supply shortages we’ve all seen, a supply shortage in getting parts to New Mexico. For instance, we have chemistry analyzers that are down today, and we have service engineers here trying to figure out if FedEx can get the parts here.

New Mexico is a fragile state socioeconomically and there’s a great public health and population health challenge.
Eric Carbonneau (TriCore): Yes, there is. We are hoping to launch remote collection sites to go to those patients. We did that last year with the National Guard during the surge. TriCore is looking at how we can do that, and we’re awaiting funding options.

Clark Day, what’s it like in Indianapolis?
Clark Day, VP of system laboratory services, Indiana University Health: We launched the ability to test our quarantined team members on day five with antigen testing. We typically have more than 1,200 team members in quarantine out of almost 38,000. We’re testing 300 to 400 team members each week, and about 54 percent of them are positive. Since launch we’ve been able to return about 150 or more people to work four or five days sooner each week by performing this antigen testing.

Our emergency departments are overrun with people showing up “just to get a test.” We have upstream communication and public relations messaging to encourage people to visit our remote sites. We’re having to refresh that messaging and reinforce it to relieve our EDs.

As for weekly testing of our own unvaccinated team members—about 10 percent of our workforce—we have decided not to pursue that, as once-weekly testing is inadequate to detect omicron and the burden on our laboratory leaders and frontline team members to test twice a week would be excessive.

I’m going to end with you, Stan Schofield. You have been a good barometer and predictor of events. Can you share your perspective on the potential peaking and then diminishment of the surge late in January?
Stan Schofield, president, NorDx, and senior VP, MaineHealth: Based on the data I have read out of England, Europe, and South Africa, around Valentine’s Day will be our peak. We’re still going up every day. It is dominant omicron. For us, I think we’ll decline Valentine’s Day and the last two weeks of February, and I hope we hold out till then, because we have denial of care, denial of service, staff are out. There was confusion around the five-day rule, but that’s getting solved quickly because it goes into effect tomorrow when we do antigen testing on day five and return to work on day six. We have hundreds of people out at the system level who are fully vaccinated and COVID positive, and many people who are boosted are sick. My money is on Valentine’s Day, and it’ll be a sweetheart deal for me if that’s true.